Bajaj HealthCare (Small Cap - Next Multibagger) Share Target 2024, 2025 To 2039
|
Bajaj HealthCare Limited |
|||
|
Price: ₹572.50 | ||
| 52 Week Low: ₹263.30 52 Week High: ₹615.00 |
|||
| Market Capital: 1,235.22 Crore (Smallcap) | |||
| Healthcare -> Drug Manufacturers—Specialty & Generic | |||
Show Table of Contents
Table of Contents
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: Bajaj HealthCare Share Price Target For 2024
- 1.1.1: Bajaj HealthCare Share Price Target Table For 2024
- 1.1.2: Short-Term Technical Outlook
- 1.2: Bajaj HealthCare Share Price Target For 2025
- 1.2.1: Bajaj HealthCare Share Price Target Table For 2025
- 1.2.2: Long-Term Technical Outlook
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: Bajaj HealthCare Share Price Target Chart and Table From 2024, 2025, 2026 to 2039
- 3: Bajaj HealthCare Brief Company Overview
- 4: Bajaj HealthCare Financial Performance
- 4.0.1: Is Bajaj HealthCare A Good Buy For Long Term?
To predict the Bajaj HealthCare's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
Bajaj HealthCare Share Price Target For 2024
The line chart displays the monthly closing prices of Bajaj HealthCare with a black line. The green line shows three potential target prices for 2024, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Bajaj HealthCare shares in 2024, see the table below.
Bajaj HealthCare Share Price Target Table For 2024
| Level | Value | Analysis |
|---|---|---|
| 2024 Target 3 | 638.17 (+11.47%) | Price Action: Chart |
| 2024 Target 2 | 626.27 (+9.39%) | Fibonacci Extension Level 23.60% |
| 2024 Target 1 | 615.0 (+7.42%) | Fibonacci Extension Level 100.00% |
| Current Price | 572.50 | Bajaj HealthCare's share price as of 23 Dec 2024 |
| Stop Loss 1 | 551.41 (-3.69%) | Price Action: Chart |
| Stop Loss 2 | 545.9 (-4.65%) | Price Action: Chart |
| Stop Loss 3 | 533.2 (-6.87%) | Price Action: 19 Dec 2024 Low |
Short-Term Technical Outlook
Current Technical Position: Bajaj HealthCare is showing bullish momentum with price above both 25-day and 50-day moving averages.
Key Technical Level: The 25-day moving average at ₹436.35 serves as the nearest technical reference point.
Historical Returns: 3-month: +41.94% | 6-month: +59.06% | 1-year: +42.37%
Bajaj HealthCare Share Price Target For 2025
The line chart displays the monthly closing prices of Bajaj HealthCare with a black line. The green line shows three potential target prices for 2025, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Bajaj HealthCare shares in 2025, see the table below.
Bajaj HealthCare Share Price Target Table For 2025
| Level | Value | Analysis |
|---|---|---|
| 2025 Target 3 | 814.29 (+42.23%) | Price Action: Chart |
| 2025 Target 2 | 799.11 (+39.58%) | Price Action: Chart |
| 2025 Target 1 | 791.2 (+38.2%) | Fibonacci Extension Level 150.00% |
| Current Price | 572.50 | Bajaj HealthCare's share price as of 23 Dec 2024 |
| Stop Loss 1 | 512.04 (-10.57%) | Price Action: Oct 2023 High |
| Stop Loss 2 | 506.92 (-11.46%) | Price Action: Chart |
| Stop Loss 3 | 494.55 (-13.62%) | Price Action: Sep 2023 High |
Long-Term Technical Outlook
52-Week Range Analysis: Bajaj HealthCare is currently trading near its 52-week high of ₹615, showing strong yearly momentum.
Long-Term Trend Analysis: The stock is maintaining a bullish long-term trend, trading above both 150-day and 250-day moving averages.
Long-Term Performance: 1-year: +42.37% | 3-year: +30.19% | 5-year: +393.35%
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
Bajaj HealthCare Share Price Target Chart and Table From 2024, 2025, 2026 to 2039
| Year | Target 1 | Target 1 YoY Chg % | Target 2 |
|---|---|---|---|
| Current Price | ₹572.50 | ||
| 2024 | ₹414.11 | -27.66% | ₹420.32 |
| 2025 | ₹480.88 | +16.12% | ₹488.09 |
| 2026 | ₹575.06 | +19.58% | ₹583.69 |
| 2027 | ₹647.01 | +12.51% | ₹656.72 |
| 2028 | ₹739.40 | +14.27% | ₹750.49 |
| 2029 | ₹832.39 | +12.57% | ₹844.88 |
| 2030 | ₹884.98 | +6.31% | ₹898.25 |
| 2031 | ₹988.78 | +11.72% | ₹1,003.61 |
| 2032 | ₹1,053.94 | +6.58% | ₹1,069.75 |
| 2033 | ₹1,152.47 | +9.34% | ₹1,169.76 |
| 2034 | ₹1,250.68 | +8.52% | ₹1,269.44 |
| 2035 | ₹1,289.08 | +3.07% | ₹1,308.42 |
| 2036 | ₹1,402.49 | +8.79% | ₹1,423.53 |
| 2037 | ₹1,460.86 | +4.16% | ₹1,482.77 |
| 2038 | ₹1,565.54 | +7.16% | ₹1,589.02 |
| 2039 | ₹1,642.50 | +4.91% | ₹1,667.14 |
Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.
Bajaj HealthCare Brief Company Overview
Bajaj Healthcare Limited: A Pharmaceutical Giant Bajaj Healthcare Limited, established in 1993, is a leading pharmaceutical company in India, catering to domestic and international markets. Key Products and Services: Amino Acids: Essential building blocks for...
protein synthesis. Nutritional Supplements: Supports overall health and well-being. Active Pharmaceutical Ingredients (APIs): Raw materials for various drug formulations. Market Presence: Bajaj Healthcare has a robust presence in India and various international markets, supplying to pharmaceutical, nutraceutical, and food industries. Reputation and Commitment: Known for its commitment to quality and innovation, Bajaj Healthcare has earned a strong reputation in the industry. Diverse Product Range: The company boasts a comprehensive product portfolio covering a wide range of therapeutic categories, including: Anti-diabetic Antibiotic Antifungal Anticonvulsant Anti-asthmatic Cardiovascular agentsBajaj HealthCare Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 1,235.22 Crore | Market valuation of Bajaj HealthCare's shares. |
| Revenue (TTM) | 475.92 Crore | Total revenue generated by Bajaj HealthCare over the past twelve months. |
| Net Income (TTM) | -13.32 Crore | Net Profit or Loss after all the expenses over the past twelve months. |
| Operating Margin | +13.44% | Income from operations as a percentage of revenue, before taxes and interest. |
| Profit Margin | -5.98% | Net income as a percentage of revenue, after all expenses. |
| Revenue Growth (Quarterly) |
+1.9% | Change in revenue compared to the previous quarter. |
| Debt-to-Equity (D/E) Ratio |
119.56 | Company's total debt divided by total shareholder equity. |
| Total Debt | 332.82 Crore | Sum of Bajaj HealthCare's current & long-term financial obligations. |
| Total Cash | 2.92 Crore | Total amount of liquid funds available to Bajaj HealthCare. |
| Beta | 0.57 | Beta is less than 1 indicating that the Bajaj HealthCare's price is less volatile than the market. |
Is Bajaj HealthCare A Good Buy For Long Term?
Bajaj Healthcare, a small-cap stock with a market capitalization of ₹1,235.22 crore, presents a mixed picture for long-term investors. While its past 5-year returns are impressive (256.49%), a significant debt of ₹332.82 crore (Q1 2024-25) against a meager cash balance of ₹2.92 crore raises concerns. Furthermore, a negative net profit of ₹13.32 crore (TTM) and a negative profit margin of -5.98% indicate financial instability. Although recent returns are positive, the substantial debt makes it a risky investment. Therefore, it's currently not a good buy for the long term; further financial improvement is needed before considering it.
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
